Under the agreement Novartis will provide Dynavax a supply of trivalent influenza vaccine, an essential component of Dynavax’s Universal Influenza Vaccine, for both clinical trial use and vaccine sales. Novartis receives an exclusive option to negotiate a joint development and commercialization agreement with Dynavax.
Under the agreement Dynavax will conduct early-stage development through a defined proof-of-concept. If Novartis exercises the right to negotiate a further agreement for development and commercialization, Dynavax would retain co-commercialization rights in the US and receive product royalties outside of the US.
Should the option not be exercised, Novartis remains committed to providing commercial supply of trivalent influenza vaccine with pre-agreed commercial terms and Dynavax retains the right to independently continue with late-stage development and commercialization.
Dino Dina, CEO and president of Dynavax, said: “This agreement with one of the world’s leading manufacturers and innovators in influenza vaccines is a fundamental step for the successful development of our universal flu vaccine. With this agreement in place we can proceed toward the clinic and to licensure through a known regulatory pathway.”